SCHEMBL4860657

SCHEMBL4860657

NS(=O)(=O)c1cc(C(=O)CCCCCl)cc2c1OCCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.41
PTGS1 P23219 2/20 0.41
CTNNB1 P35222 8/20 0.38
WNT3A P56704 8/20 0.38
CA2 P00918 4/20 0.34
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA3 P07451 2/20 0.34
CA4 P22748 2/20 0.34
CA6 P23280 2/20 0.34
CA5A P35218 2/20 0.34
CA7 P43166 2/20 0.34
CA9 Q16790 2/20 0.34
CA13 Q8N1Q1 2/20 0.34
CA14 Q9ULX7 2/20 0.34
CA5B Q9Y2D0 2/20 0.34
NPC1 O15118 3/20 0.32
RAB9A P51151 2/20 0.32
GRM1 Q13255 1/20 0.32
NFKB1 P19838 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4861134 0.93 PTGS2 (0.47) PTGS2PTGS1CTNNB1WNT3ACA2
SCHEMBL4852362 0.90 PTGS2 (0.42) PTGS2PTGS1CTNNB1WNT3ANPC1
SCHEMBL4859405 0.82 PTGS2 (0.48) PTGS2PTGS1CTNNB1WNT3A
SCHEMBL4855167 0.82 NPC1 (0.43) PTGS2PTGS1CTNNB1WNT3ACA2
SCHEMBL5308047 0.81 PTGS2 (0.47) PTGS2PTGS1CTNNB1WNT3ACA2
SCHEMBL5310504 0.81 NPC1 (0.37) PTGS2PTGS1CTNNB1WNT3ACA2
SCHEMBL5310834 0.80 PTGS1 (0.48) PTGS2PTGS1CTNNB1WNT3ACA2
SCHEMBL28753783 0.80 PTGS2 (0.51) PTGS2PTGS1CA2CA12CA1
SCHEMBL4855311 0.79 AKT1 (0.37) PTGS2PTGS1CA2
SCHEMBL4860602 0.79 PTGS2 (0.47) PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7462628-B2 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-09 US disclosed
US-7462628-B2 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-09 US disclosed
US-7462628-B2 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-09 US disclosed
US-7138533-B2 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-11-21 US disclosed
US-7132547-B2 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-11-07 US disclosed
US-20060211675-A1 Preventives/remedies for urinary disturbance ISHIHARA YUJI 2006-09-21 US disclosed
US-20060063769-A1 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-03-23 US disclosed
US-20050197362-A1 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-09-08 US disclosed
EP-1466625-A1 PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE Takeda Chemical Industries, Ltd. (JP) 2004-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063769-A1 Preventives/remedies for urinary disturbance ACHE, BPHL, CHRM1 PTGS2 610/4885PTGS1 211/4885CTNNB1 2598/4885
US-20050197362-A1 Preventives/remedies for urinary disturbance ACHE, BPHL, CHRM1 PTGS2 610/4885PTGS1 211/4885CTNNB1 2598/4885
US-20060211675-A1 Preventives/remedies for urinary disturbance ACHE, BPHL, ACE PTGS2 474/4885PTGS1 417/4885CTNNB1 4153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.